MannKind Corp (MNKD): Market Cap to Revenue

Corporate company logo of MannKind Corp. (MNKD)

MannKind Corporation (MNKD) maintains stable management as it develops its inhalation platform, a trend reflected in the upward volatility of the P/S ratio. Profit growth is driven by Tyvaso DPI royalties and a reduction in liabilities, while the value of 3.20 characterizes this level of market valuation. Financial stability is further bolstered by the implementation of ESG standards in production and the recycling of device components, optimizing the company's environmental footprint.

Price-to-Revenue Ratio: MannKind Corp (MNKD) for 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Afrezza (MNKD)

- share price and consensus valuation forecast:
Price Performance Chart MannKind Corp|MNKD - Price Target Chart
- stock exchange capitalization data:
Market Valuation Afrezza|MNKD - Enterprise Value
- book value of equity indicators:
Book Value per Share MannKind|MNKD - Company Book Value|Capitalization to Book Value Ratio mannkindcorp.com|MNKD - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio MannKind Corporation|MNKD - Long-Term Debt to Equity|Short-Term Debt to Capital MannKind Corporation|MNKD - Company Aggregate Debts|Debts to Net Assets MannKind|MNKD - Company Long-Term Debt|Company Short-Term Indebtedness MannKind|Immediate Liquidity Ratio mannkindcorp.com
- company profitability and valuation multiples indicators:
MNKD - Net Income|Expected Net Income MannKind Corporation|MNKD - P/E Multiple|Projected Price to Earnings Afrezza|MNKD - Price/Earnings to Growth Ratio|Company Value to EBITDA MannKind|MNKD - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year MannKind|MNKD - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months mannkindcorp.com|MNKD - Earnings per share growth in current year|Expected net earnings per share growth next year MannKind Corporation
- total revenue and sales volume data:
MNKD - Company Revenue|Company Future Revenue MannKind|MNKD - P/S Multiple|Forward P/S Multiple MannKind Corporation|MNKD - Revenue Growth YoY (Last 12 Months)
General company analysis:MNKD, MannKind Corp
Manufactured products of MannKind Corp.

Stable pharmaceutical capacity utilization and the automation of packaging lines at MannKind Corporation (MNKD) create a reliable foundation for revenue scaling. By analyzing the P/S ratio chronology, an investor determines the market value of a single dollar of sales, which allows for an assessment of the expectations priced in and an understanding of how resilient current quotes are to potential fluctuations in business growth rates.

Competitors of MannKind Corporation

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|Price-to-Revenue Ratio Amphastar Pharmaceuticals Inc AMPH|P/S Multiple Pacira PCRX|ARS Pharmaceuticals Inc - P/S Multiple|TBPH - P/S Multiple|AQST (Aquestive Therapeutics) - Market Cap to Revenue|scPharmaceuticals, Inc. (SCPH) - P/S Multiple|Market Cap to Revenue TECX|P/S Multiple Tonix Pharma|Market Cap to Revenue SXTC (SXT Pharmaceuticals)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)